An internal audit identified major inconsistencies and missing data in key registry fields, including primary outcomes. These issues mean we can no longer ensure the validity of the primary endpoints.

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

Inclusion Criteria:

• Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
• Signed and dated ICF.
• Age 18 years or older at day ICF is signed.

Exclusion Criteria:

• Currently enrolled in a clinical trial.
• Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
• Participant is pregnant or breastfeeding.

Participants who have been prescribed Ferring ADSTILADRIN at the participating sites will be enrolled.